Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
AG957 is a tyrphostin that targets transforming Bcr-Abl fusion proteins (p185Bcr-Abl, p210Bcr-Abl), as well as normal c-Abl (IC50s = 4.3, 1, and 7.1 µM, respectively, for human proteins).1 It also inhibits epidermal growth factor receptor (IC50 = 0.25 µM).1 As the constitutively-active 210 kDa Bcr-Abl fusion protein commonly occurs in chronic myelogenous leukemia (CML) cells, AG957 is commonly used to study Bcr-Abl signaling in the CML K562 cell line.2,3 AG957 is also used to study signaling through c-Abl.4
WARNING This product is not for human or veterinary use.
1. Selective interactions of transforming and normal abl proteins with ATP, tyrosine-
2. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-
3. Protein kinase Cι activity is necessary for Bcr-
4. c-